125 related articles for article (PubMed ID: 11502994)
1. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study.
Yildiz A; Cine N; Akkaya V; Sahin S; Ismailoğlu V; Türk S; Bozfakioğlu S; Sever MS
Transplantation; 2001 Aug; 72(3):542-4. PubMed ID: 11502994
[TBL] [Abstract][Full Text] [Related]
2. [Erythrocytosis post kidney transplantation and its pharmacological treatment: angiotensin converting enzyme inhibitors or angiotensin receptor blockers in a case].
Duclos J
Rev Med Chil; 2000 Feb; 128(2):211-2. PubMed ID: 10962891
[TBL] [Abstract][Full Text] [Related]
3. Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis.
Wang AY; Yu AW; Lam CW; Yu LM; Li PK; Goh J; Lui SF
Am J Kidney Dis; 2002 Mar; 39(3):600-8. PubMed ID: 11877580
[TBL] [Abstract][Full Text] [Related]
4. Renin-angiotensin system polymorphisms and hemoglobin level in renal allografts: a comparative study between losartan and enalapril.
Noroozianavval M; Argani H; Aghaeishahsavari M; Veisi P; Ghorbanihaghjo A; Rashtchizadeh N; Jabbarpourbonyadi M; Hamzeiy H
Transplant Proc; 2007 May; 39(4):1018-22. PubMed ID: 17524880
[TBL] [Abstract][Full Text] [Related]
5. Influence of angiotensin-converting enzyme polymorphism gene, IGF-1, and other factors in the response rate of hematocrit to enalapril treatment in patients with posttransplant erythrocytosis.
Jimeno L; Rodado R; Barrios Y; Campos M; Llorente S; Nicolas F; Minguela A
Transplant Proc; 2005 Mar; 37(2):1012-3. PubMed ID: 15848608
[TBL] [Abstract][Full Text] [Related]
6. Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors.
MacGregor MS; Rowe PA; Watson MA; Rodger RS; Junor BJ; Briggs JD
Nephron; 1996; 74(3):517-21. PubMed ID: 8938674
[TBL] [Abstract][Full Text] [Related]
7. Effect of the angiotensin-converting enzyme inhibitor enalapril on post-transplant erythrocytosis.
Marubayashi S; Yamamoto H; Shibata S; Fudaba Y; Miyata Y; Fukuma K; Okada K; Hinoi T; Ikeda M; Maeda T; Oshiro Y; Dohi K
Hiroshima J Med Sci; 1998 Sep; 47(3):121-4. PubMed ID: 9810784
[TBL] [Abstract][Full Text] [Related]
8. Enalapril and losartan affect lipid peroxidation in renal transplant recipients with renin-angiotensin system polymorphisms.
Rashtchizadeh N; Aghaeishahsavari M; Argani H; Noroozianavval M; Veisi P; Ghorbanihaghjo A
Clin Biochem; 2007 Feb; 40(3-4):194-200. PubMed ID: 17222813
[TBL] [Abstract][Full Text] [Related]
9. Correction of post-renal transplant erythrocytosis by enalapril.
Rostaing L; Boisseau M; Huyn A; Durand D
Scand J Urol Nephrol; 1995 Dec; 29(4):399-406. PubMed ID: 8719356
[TBL] [Abstract][Full Text] [Related]
10. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA.
Schmidt A; Gruber U; Böhmig G; Köller E; Mayer G
Nephrol Dial Transplant; 2001 May; 16(5):1034-7. PubMed ID: 11328912
[TBL] [Abstract][Full Text] [Related]
11. Effect of angiotensin II type-1 receptor blockers on stable allograft kidneys: prospective randomized study.
Nouri-Majalan N; Ghafari A; Moghaddasi S
Transplant Proc; 2009 Sep; 41(7):2832-4. PubMed ID: 19765449
[TBL] [Abstract][Full Text] [Related]
12. Long term effects of ACE inhibitors on the erythrocytosis in renal transplant recipients.
Lal SM; Trivedi HS; Ross G
Int J Artif Organs; 1995 Jan; 18(1):13-6. PubMed ID: 7607751
[TBL] [Abstract][Full Text] [Related]
13. Prevention of DNA damage in renal transplantation by losartan and enalapril: the role of renin-angiotensin system polymorphisms.
Ghorbanihaghjo A; Veisi P; Argani H; Aghaeishahsavari M; Noroozianavval M; Rashtchizadeh N; Mesgari M; Safa J; Babaei H
Clin Exp Nephrol; 2008 Feb; 12(1):65-73. PubMed ID: 18175066
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study.
Zhu X; Chen J; Han F; Cheng M; Xu L; Zhang L; Ding X; Le Y
Transplant Proc; 2009 Nov; 41(9):3736-42. PubMed ID: 19917377
[TBL] [Abstract][Full Text] [Related]
15. Neutropenia after treatment of posttransplantation erythrocytosis with enalapril.
Donadio C; Lucchesi A
Transplantation; 2001 Aug; 72(3):553-4. PubMed ID: 11503000
[No Abstract] [Full Text] [Related]
16. Efficacy of enalapril after ineffective theophylline treatment on erythrocytosis after renal transplantation.
Yagisawa T; Toma H; Yaguchi H; Tomaru M; Iijima Y; Suzuki H; Nakada T
Int Urol Nephrol; 1997; 29(3):363-7. PubMed ID: 9285312
[TBL] [Abstract][Full Text] [Related]
17. Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients.
Sakallı H; Baskın E; Bayrakcı US; Moray G; Haberal M
Exp Clin Transplant; 2014 Aug; 12(4):310-3. PubMed ID: 24447308
[TBL] [Abstract][Full Text] [Related]
18. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels.
Perazella M; McPhedran P; Kliger A; Lorber M; Levy E; Bia MJ
Am J Kidney Dis; 1995 Sep; 26(3):495-500. PubMed ID: 7645558
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized, open labeled crossover trial of fosinopril and theophylline in post renal transplant erythrocytosis.
Trivedi H; Lal SM
Ren Fail; 2003 Jan; 25(1):77-86. PubMed ID: 12617335
[TBL] [Abstract][Full Text] [Related]
20. Effects of losartan on the treatment of posttransplant erythrocytosis.
Navarro JF; García J; Macía M; Mora C; Chahin J; Gallego E; Méndez ML; del Castillo N
Clin Nephrol; 1998 Jun; 49(6):370-2. PubMed ID: 9696433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
